Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 5Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Diseases 1

Interventions

pembrolizumab 14Cisplatin 13Specimen Handling 11Magnetic Resonance Spectroscopy 7Brachytherapy 7Bevacizumab 7Radiotherapy 6atezolizumab 5Platinum 5Paclitaxel 5Nivolumab 5Human Papillomavirus DNA Tests 5Gemcitabine 5Colposcopy 5Carboplatin 5Blood Specimen Collection 5Radiation 4Fulvestrant 4lenvatinib 3Surveys and Questionnaires 3Radiation Dose Hypofractionation 3Drug Therapy 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3zimberelimab 2tisotumab vedotin 2spartalizumab 2palbociclib 2camrelizumab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Imlunestrant × 90 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡